Editas Medicine Inc (NASDAQ: EDIT) on Friday, plunged -8.82% from the previous trading day, before settling in for the closing price of $4.08. Within the past 52 weeks, EDIT’s price has moved between $0.91 and $4.54.
Healthcare Sector giant saw their annual sales slid by -1.48% over the last five years. The company achieved an average annual earnings per share of 29.37%. With a float of $89.11 million, this company’s outstanding shares have now reached $89.92 million.
Editas Medicine Inc (EDIT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Editas Medicine Inc is 0.90%, while institutional ownership is 47.43%. The most recent insider transaction that took place on Sep 03 ’25, was worth 1,843. In this transaction EVP, CHIEF SCIENTIFIC OFFICER of this company sold 710 shares at a rate of $2.60, taking the stock ownership to the 69,490 shares. Before that another transaction happened on Sep 03 ’25, when Company’s SVP, Chief Financial Officer sold 458 for $2.60, making the entire transaction worth $1,189. This insider now owns 16,369 shares in total.
Editas Medicine Inc (EDIT) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.75 earnings per share (EPS) for the period topping the consensus outlook (set at -0.77) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.49% during the next five years compared to -1.48% drop over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Editas Medicine Inc (EDIT) is currently performing well based on its current performance indicators. A quick ratio of 2.77 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.85, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.09 in one year’s time.
